Emerging Treatments for Reactive Cutaneous Capillary Endothelial Proliferation

BACKGROUND: Reactive cutaneous capillary endothelial proliferation (RCCEP) is a common, burdensome adverse event that occurs in up to 88% of patients treated with camrelizumab. Without treatment, RCCEP is associated with social stigma and low quality of life. However, the optimal management of RCCEP...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yi, Chen, Tiancheng, Zhang, Chao, Pan, Weihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Therapeutic Round
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162724/
https://www.ncbi.nlm.nih.gov/pubmed/37151267
http://dx.doi.org/10.4103/ijd.ijd_505_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162724/
https://www.ncbi.nlm.nih.gov/pubmed/37151267
http://dx.doi.org/10.4103/ijd.ijd_505_22

Ejemplares similares